Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 16:20 save search
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Published: 2024-03-16 (Crawled : 16:20) - prnewswire.com
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
| Email alert
Add to watchlist
precision cancer research impact diagnostics
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
lumakras cancer plus
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
ev-302 padcev bladder cancer trial
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Published: 2023-10-22 (Crawled : 16:20) - globenewswire.com
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
tivdak cancer global trial
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
retevmo lung congress symposium cancer cell thyroid results
New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant lung disease cancer cell risk plus show study
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2023-06-04 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant lung cancer cell therapy show study
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K
|
| Email alert
Add to watchlist
eli-002 asco positive cancer pancreatic risk meeting therapeutics study
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
| Email alert
Add to watchlist
afm24 lung update cancer cell meeting
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
Published: 2023-04-29 (Crawled : 16:20) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | $9.17 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
xtandi cancer risk plus
Global Liver Cancer Drugs Strategic Market Report to 2030: Targeted Therapies Grow in Popularity
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
liver global report cancer market
Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day
Published: 2023-02-04 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
day care report health pilot cancer
Global Proteomics Market Research Report 2022-2027: Increasing Prominence of Nano-proteomics Gaining Traction as Rising Prevalence of Cancer and Associated Genetic Disorders Driving Growth
Published: 2023-01-21 (Crawled : 16:20) - prnewswire.com
BIO | $279.73 -0.46% 0.0% 290K
|
Health Technology
| Email alert
Add to watchlist
WAT | $296.1 0.64% 0.0% 470K
|
Health Technology
| Email alert
Add to watchlist
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
PKI | $115.24 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
BRKR | $77.725 -1.06% -1.07% 1.3M
|
Health Technology
| Email alert
Add to watchlist
research global report genetic cancer growth market
NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER
Published: 2022-06-05 (Crawled : 16:20) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
vectibix cancer
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
Published: 2022-06-05 (Crawled : 16:20) - globenewswire.com
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
| Email alert
Add to watchlist
cancer
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
Published: 2022-05-17 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.0%
H: 5.05%
C: 4.2%
media health cancer
LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Published: 2022-04-10 (Crawled : 16:20) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
lumakras 100 cancer
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
Published: 2022-04-06 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -1.14%
H: 1.51%
C: -7.37%
day veterinary conference diarrhea health cancer
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
Published: 2022-03-09 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 1.83%
H: 18.92%
C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer vaccine phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.